



Press release

## **Notification Obligation Regarding Holders of Significant Interest in SHL Telemedicine Ltd.; Notification Deadline on April 30, 2014**

**Tel Aviv/Zurich, 24 April 2014** – Under the amended Stock Exchange Act (Börsengesetz – BEHG) and the amended Stock Exchange Ordinance (Börsenverordnung – BEHV), disclosure requirements for significant shareholders pursuant to Art. 20 of the Swiss Stock Exchange Act also apply to companies which are registered abroad and have their primary listing on the SIX Swiss Exchange, such as SHL Telemedicine Ltd. (the “Company” or “SHL”).

Shareholders of SHL, whose voting rights in the Company reached or exceeded relevant triggering thresholds (3, 5, 10, 15, 20, 25, 33.33, 50 and 66.66 % of voting rights) already prior to May 1, 2013, and have not changed since then, are hereby reminded that they have to notify the Disclosure Office of the SIX Swiss Exchange and SHL of their holdings by April 30, 2014

For more information pls. refer to the SIX website at: [http://www.six-exchange-regulation.com/obligations/disclosure\\_en.html](http://www.six-exchange-regulation.com/obligations/disclosure_en.html)

### **About SHL Telemedicine**

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. The Company operates in Israel, Germany, India and the United States in one business segment, Telemedicine services. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and has an ADR program listed over-the counter; Symbol: SMDCY. For more information please visit our web site at [www.shl-telemedicine.com](http://www.shl-telemedicine.com).

### **Contacts:**

Erez Alroy  
Co-CEO  
P: +972 3 5612212,  
[ereza@shl-telemedicine.com](mailto:ereza@shl-telemedicine.com)

Martin Meier-Pfister  
IRF Communications  
P: +41 43 244 81 40  
[shl@irfcom.ch](mailto:shl@irfcom.ch)

Garth Russell / Josh Dver  
KCSA Strategic Communications  
P: 212-896-1250 / 212-896-1239  
[grussell@kcsa.com/jdver@kcsa.com](mailto:grussell@kcsa.com/jdver@kcsa.com)

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.